1 Chapter 1Figure 1.1 Monomers for side-chain-linked amino acids.Figure 1.2 Compounds for a block copolymer.Figure 1.3 Hydrophilic methacrylamide-based monomers.Figure 1.4 Monomers for hydrophilic polymers.Figure 1.5 Bisacrylamide monomers.Figure 1.6 Polyfunctional methacrylate compounds.Figure 1.7 Hydrophobic monomers.Figure 1.8 Hydrophilic monomers.Figure 1.9 Hydrophobic strengthening monomers.Figure 1.10 Crosslinking monomers.Figure 1.11 Monomers and comonomers.Figure 1.12 Azo initiators.Figure 1.12 (cont) Peroxy initiators.Figure 1.12 (cont) Photoinitiators.Figure 1.12 (cont) Photoinitiators.Figure 1.13 Tinting agents.Figure 1.13 (cont) Tinting agents.Figure 1.14 2-Alkenyl azlactones.Figure 1.14 (cont) Cycloalkyl azlactones.Figure 1.15 2-Isopropenyl-4,4-dimethyl-2-oxazolin-5-one.Figure 1.16 n-Nonanol.Figure 1.17 Diethylene glycol monoethyl ether.Figure 1.18 Methyl enanthate or Methyl heptanoate.Figure 1.19 3-[Tris(trimethylsiloxy)silyl]propyl methacryloyloxyethyl succinate.Figure 1.20 Monomers for telechelic macromonomers (20).Figure 1.21 Nucleating agents (31).Figure 1.22 Cross-sectional view of a contact lens mold assembly (31).Figure 1.23 Synthesis of N-carbomethoxymethyl-N-methacryloylamidopropyl-N,N-dime...Figure 1.24 Sugars in hyaluronic acid.Figure 1.25 Crosslinking agents.Figure 1.26 Monomers.Figure 1.27 Poly(siloxane) monomers.Figure 1.28 Trifluoromethanesulfonic acid.Figure 1.29 Drugs.Figure 1.30 Target biomarkers.Figure 1.30 (cont) Target biomarkers.Figure 1.31 Prodan (1-(6-(Dimethylamino)naphthalen-2-yl)propan-1-one).Figure 1.32 Synthesis of Quin-C18.Figure 1.33 Block diagram of sensor (60).Figure 1.34 Hormones.Figure 1.35 Chipless functional contact lens (61).Figure 1.36 Electronic contact lens system (65).Figure 1.37 Accessory device (65).Figure 1.38 Beam pattern generated by an accessory device (65).Figure 1.39 Lens manufacturing system (103).Figure 1.40 4-(Phenyldiazenyl) phenyl methacrylate.Figure 1.41 UV-blocking agents.Figure 1.42 Silicone monomers.Figure 1.43 Monomers for non-silicone hydrogels.Figure 1.44 Crosslinking agents.Figure 1.45 Catalysts.Figure 1.46 Hydrophilic monomers.Figure 1.47 Initiators.Figure 1.48 Catalysts.Figure 1.49 Peroxides.Figure 1.49 (cont) Peroxides.Figure 1.50 Monomers.Figure 1.51 Isocyanates.Figure 1.51 (cont) 1,3,5-Tris(6-isocyanatohexyl) biuret.Figure 1.52 2-Isocyanatoethyl methacrylate.Figure 1.53 Contact lens structure (128).Figure 1.54 Contact angle of water of a silicone rubber sheet coated by a methan...Figure 1.55 Synthesis of 2-methacryloyloxyethyl phosphorylcholine and (2-methacr...Figure 1.56 Bis(trimethylsilyloxy)methylsilylpropyl glycerol methacrylate.Figure 1.57 Bicinchoninic acid.Figure 1.58 4’,6-Diamidin-2-phenylindol.Figure 1.59 Chitosan structure.Figure 1.60 Naphazoline.Figure 1.61 2-Methacryloxyethyl phosphate.Figure 1.62 Ligand concentrations versus naphazoline content.Figure 1.63 Monomers for an ophthalmic drug delivery system.

      2 Chapter 2Figure 2.1 Special contact lens (8).Figure 2.2 Decentered contact lens structure (16).Figure 2.3 Front of a stabilized contact lens (17).Figure 2.4 Mold insert (19).Figure 2.5 Side elevation of a contact lens (21).Figure 2.6 Contact lens mold assembly (22).Figure 2.7 1-Vinyl-2-pyrrolidinone.Figure 2.8 Monomeric acids for mat-forming polymers.Figure 2.9 Comonomers for mat production.Figure 2.9 (cont) Comonomers for mat production.Figure 2.9 (cont) Comonomers for mat production.Figure 2.10 Hydrophilic monomers.Figure 2.11 Crosslinking agents.Figure 2.12 Genipin.Figure 2.13 Di-sec-butyl peroxy dicarbonate.Figure 2.14 Hydrazine salts.Figure 2.15 Etidronic acid.Figure 2.16 Compounds in isotonic buffered saline solution.Figure 2.17 Method of inserting a contact lens (51).

      3 Chapter 3Figure 3.1 Benzalkonium Chlorides.Figure 3.2 Lens materials.Figure 3.3 Diethylenetriamine penta(methylenephosphonic acid).Figure 3.4 Equilibrium water content vs. monomer content (84).Figure 3.5 Transparency vs. monomer content (84).Figure 3.6 Oxygen permeability vs. monomer content (84).Figure 3.7 Amount of Staphylococcus aureus on the surface vs. monomer content (8...Figure 3.8 Optical measurement system (112).Figure 3.9 Swept source optical coherence tomography system (107).

      4 Chapter 4Figure 4.1 α-Cyclodextrin.Figure 4.2 Vitamin E.Figure 4.3 Oleic acid.Figure 4.4 Cationic drugs.Figure 4.5 Unsaturated fatty acids.Figure 4.6 Betaxolol hydrochloride.Figure 4.7 Chemicals for the synthesis of a HEMA-chitosan polymer.Figure 4.8 N,N’-Carbonyldiimidazole and its methacrylic acid derivative.Figure 4.9 Cyclosporine A.Figure 4.10 Disodium cromoglycate.Figure 4.11 Disuccinimidyl carbonate.Figure 4.12 Biotin.Figure 4.13 Tobramycin.Figure 4.14 Vancomycin.Figure 4.15 Amount of drug release vs. time (64).Figure 4.16 Diazeniumdiolate.Figure 4.17 Acetazolamide.Figure 4.18 Flurbiprofen.Figure